Rethinking the Role of Inhaled Antibiotics in Ventilator-Associated Pneumonia: New Evidence From a Landmark Meta-Analysis

Ventilator-associated pneumonia (VAP) remains one of the most common and lethal infections in the ICU, affecting 10–25% of mechanically ventilated patients and carrying an all-cause mortality of 25–50%. Despite decades of prevention bundles, VAP continues to drive prolonged ventilation, extended ICU stays, and excess antibiotic exposure — often with multidrug-resistant (MDR) organisms.

Inhaled antibiotics have long been proposed as an adjunct to systemic therapy, theoretically delivering high drug concentrations directly to the pulmonary parenchyma while minimizing systemic toxicity. Yet their place in routine practice has remained contentious: the 2016 IDSA/ATS guidelines issued only a weak recommendation for inhaled agents in MDR organisms, supported by very low-quality evidence, and the landmark INHALE phase 3 trial (2019) failed to demonstrate a survival benefit with inhaled amikacin adjunctive to intravenous therapy.

A systematic review and meta-analysis published in Critical Care Medicine in June 2026 now offers the most comprehensive synthesis of this evidence to date — and the results are clinically important enough to revisit this therapeutic question.

What the Authors Did

This was a comprehensive systematic review and meta-analysis designed to evaluate the efficacy and safety of adjunctive inhaled antibiotics for the treatment of VAP. The investigators searched multiple databases through May 31, 2025, identifying randomized controlled trials (RCTs) and nonrandomized studies comparing inhaled antibiotics added to standard intravenous therapy versus intravenous therapy alone (or placebo/blank control) in adult ICU patients with VAP. The primary analysis included 32 RCTs, with 41 non-RCTs incorporated in prespecified sensitivity analyses. Subgroup analyses were stratified by VAP-only populations versus broader pneumonia cohorts, and the investigators applied trial sequential analysis and GRADE methodology to assess the certainty of evidence.

The study evaluated four primary outcomes: clinical cure, all-cause mortality, microbiological eradication, and emergence of new drug resistance. Secondary outcomes included ICU length of stay, duration of mechanical ventilation, and organ dysfunction. Meta-regression was performed to explore sources of heterogeneity and identify whether specific antibiotic classes or patient subgroups drove the observed treatment effects.

Key Findings

• Improved clinical cure: Inhaled antibiotics significantly improved clinical cure compared with placebo (16 RCTs; n = 1,425; RR 1.24; 95% CI 1.07–1.43), with consistent findings in VAP-only patients (11 RCTs; n = 775; RR 1.29; 95% CI 1.10–1.52).

• Reduced all-cause mortality: Inhaled antibiotics were associated with a significant reduction in all-cause mortality (21 RCTs; n = 1,855; RR 0.84; 95% CI 0.71–0.98) — a finding that persisted in sensitivity analyses incorporating nonrandomized studies.

• Enhanced microbiological eradication: Inhaled antibiotics improved microbiological eradication rates (20 RCTs; n = 1,805; RR 1.42; 95% CI 1.27–1.58), a mechanistically plausible benefit given the high local drug concentrations achievable via inhalation.

• Reduced emergence of drug resistance: In contrast to concerns that aerosolized agents might foster resistance, pooled data demonstrated a reduction in emergence of new resistance in the inhaled antibiotic group.

• No signal for increased systemic toxicity: There was no significant increase in nephrotoxicity or bronchospasm across included trials.

• Benefit concentrated in VAP populations: Subgroup analyses consistently showed larger and more statistically robust treatment effects when restricted to true VAP patients, as opposed to heterogeneous pneumonia cohorts.

Clinical Interpretation

This meta-analysis provides the most robust quantitative evidence to date supporting the use of adjunctive inhaled antibiotics in mechanically ventilated patients with VAP. The mortality reduction (RR 0.84), though modest, is clinically meaningful in a population carrying a baseline mortality of 25–50%. The concurrent improvements in clinical cure, microbiological eradication, and — perhaps most counterintuitively — resistance emergence, paint a coherent pharmacological picture: high local drug concentrations achieved by inhalation may overcome the pharmacokinetic-pharmacodynamic limitations inherent to systemic therapy in the poorly perfused, consolidated lung.

However, critical appraisal demands caution. This meta-analysis aggregates studies using heterogeneous inhaled antibiotics (colistin, tobramycin, amikacin, gentamicin), varying nebulization devices (jet, ultrasonic, vibrating mesh), diverse patient populations, and inconsistent definitions of VAP across trials. The landmark INHALE phase 3 trial — the largest and most rigorously designed individual RCT in this space — failed to demonstrate a survival benefit with inhaled amikacin, reminding us that meta-analytic pooling can mask null effects in well-conducted individual trials. Furthermore, only a fraction of included studies used vibrating mesh nebulizers with standardized delivery protocols, and suboptimal aerosol delivery to the alveolar space remains a major practical concern. The GRADE certainty of evidence for the mortality outcome remains moderate at best, given residual heterogeneity and the predominance of single-center trials. These findings are practice-informing, not yet practice-mandating.

Impact on Clinical Practice

This meta-analysis strengthens the rationale for considering adjunctive inhaled antibiotics — particularly in VAP due to MDR gram-negative organisms such as Pseudomonas aeruginosa or Acinetobacter baumannii where systemic options are limited. Clinicians should prioritize vibrating mesh nebulizers and ensure optimal delivery conditions (appropriate ventilator settings, humidification management, circuit placement) before attributing treatment failure to the drug rather than the delivery system. Standard intravenous therapy with appropriate source control and VAP prevention bundles should remain the cornerstone of management and must not be deprioritized. Importantly, the resistance data in this analysis should not be interpreted as a license for indiscriminate use — stewardship principles remain essential, and inhaled agents should be reserved for patients with confirmed VAP, not empirically deployed for all ventilated patients. A formal guideline update from IDSA/ATS or SCCM synthesizing this new data is warranted, and this meta-analysis will likely serve as a key reference for such efforts.

Based on the current evidence, would you prescribe adjunctive inhaled antibiotics for confirmed VAP due to MDR gram-negative pathogens?

• 0%Yes, routinely in eligible patients
• 0%Yes, but only as salvage therapy when IV options are limited
• 0%Maybe, but I would like stronger guideline recommendations f
• 0%No, current evidence is insufficient to change my practice

ICU Reach Clinical Pearls

1. Delivery technique is everything. Vibrating mesh nebulizers positioned in the inspiratory limb of the ventilator circuit, with temporary humidifier bypass and optimized ventilator settings, are essential to achieve therapeutic alveolar drug concentrations. Jet nebulizers with non-optimized circuits may deliver negligible drug beyond the endotracheal tube, explaining discordant trial results.

2. VAP subtype matters. The benefit of inhaled antibiotics in this meta-analysis was most robust when restricted to true VAP populations — not heterogeneous HAP cohorts. Patient selection is critical: focus on confirmed VAP with gram-negative organisms, especially MDR pathogens where systemic pharmacokinetics are unfavorable.

3. A mortality reduction signal demands prospective validation. The RR of 0.84 for all-cause mortality is encouraging but should be interpreted with caution given between-study heterogeneity. Future multicenter, adequately powered RCTs with standardized delivery protocols and GRADE-informed endpoints are urgently needed before inhaled antibiotics can be considered a standard adjunct for all VAP patients.

References

1. Inhaled Antibiotics to Treat Ventilator-Associated Pneumonia: A Systematic Review and Meta-Analysis. Critical Care Medicine. June 2026; 54(6):1293–1308. https://journals.lww.com/ccmjournal/fulltext/2026/06000/inhaled_antibiotics_to_treat_ventilator_associated.2.aspx PubMed PMID: 41837717

2. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases. 2016;63(5):e61–e111. https://academic.oup.com/cid/article/63/5/e61/2237650

3. Wunderink RG, Bhavnani SM, Bhavnani SM, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. The Lancet Infectious Diseases. 2020;20(3):330–340. https://www.thelancet.com/article/S1473-3099(19)30574-2/fulltext

4. Royer S, Demendoça-Ramos MT, et al. Epidemiology and Burden of Ventilator-Associated Pneumonia among Adult Intensive Care Unit Patients. Antibiotics. 2024;13(4):290. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11047600/

5. Rello J, Solé-Lleonart C, Rouby JJ, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clinical Microbiology and Infection. 2017;23(9):629–639. https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(17)30187-8/fulltext

6. Haesler E, et al. Aerosolized Antibiotic Therapy in Mechanically Ventilated Patients. American Journal of Respiratory and Critical Care Medicine. 2024;210(6):730–740. https://www.atsjournals.org/doi/full/10.1164/rccm.202402-0437CP

7. Bassetti M, Giacobbe DR, Giamarellos-Bourboulis EJ, et al. Efficacy of adjunctive inhaled colistin and tobramycin for ventilator-associated pneumonia: systematic review and meta-analysis. BMC Pulmonary Medicine. 2024;24:231. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11064396/

Published by ICU Reach | Evidence-Based Critical Care Education Reviewed: June 23, 2026